Literature DB >> 25689036

Expression of CYP3A4 and CYP3A7 in Human Foetal Tissues and its Correlation with Nuclear Receptors.

Stina Betts1, Linda Björkhem-Bergman2, Anders Rane1, Lena Ekström1.   

Abstract

Previous reports have suggested that the nuclear receptors vitamin D receptor (VDR), peroxisome proliferator-activated receptor α (PPARα), pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are involved in the regulation of the drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 expression in adults. The aim of this study was to investigate the gene expression of CYP3A4 and the foetal CYP3A7 in human foetal tissues and their relation to gene expression and genetic variations in the nuclear receptors VDR, PPARα, PXR and CAR. We determined the relative expression of CYP3A4 and CYP3A7 and these nuclear receptors in foetal livers, intestines and adrenals, using quantitative PCR. In addition, the expression of these enzymes was also analysed in adult liver. There was a high interindividual variability in CYP3A4 and CYP3A7, 49 times and 326 times, respectively. Both CYP3A4 and CYP3A7 had the highest expression in the liver. There were significant correlations (p < 0.001) between the nuclear receptors studied and the expression of CYP3A4 and CYP3A7 in foetal liver, as well as the expression of CYP3A4 in foetal intestine. Polymorphisms in the VDR gene, rs1544410 and rs1523130 (TaqI), in the PXR gene, rs1523130, and in the PPARα gene, rs4253728, were not correlated with CYP3A4 or CYP3A7 expression. However, C-homozygous individuals of the TaqI VDR polymorphism had 60% lower VDR gene expression (p < 0.05), than individuals carrying one or two T alleles. In conclusion, differences in the expression of nuclear receptors might determine the variability in CYP3A4 and CYP3A7 expression observed in foetal liver.
© 2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25689036     DOI: 10.1111/bcpt.12392

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  16 in total

1.  Hepatic expression of transcription factors affecting developmental regulation of UGT1A1 in the Han Chinese population.

Authors:  Ya-Li Nie; Hang He; Jiang-Feng Li; Xiang-Guang Meng; Liang Yan; Pei Wang; Shu-Jie Wang; Hong-Zheng Bi; Li-Rong Zhang; Quan-Cheng Kan
Journal:  Eur J Clin Pharmacol       Date:  2016-10-05       Impact factor: 2.953

Review 2.  A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms.

Authors:  A S Khazali; A M Clark; A Wells
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

Review 3.  Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Authors:  Haixing Li; Jed N Lampe
Journal:  Arch Biochem Biophys       Date:  2019-08-22       Impact factor: 4.013

4.  A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.

Authors:  Maïlys De Sousa Mendes; Gabrielle Lui; Yi Zheng; Claire Pressiat; Deborah Hirt; Elodie Valade; Naïm Bouazza; Frantz Foissac; Stephane Blanche; Jean-Marc Treluyer; Saik Urien; Sihem Benaboud
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

5.  Peroxisome Proliferator-Activated Receptor α Activation Suppresses Cytochrome P450 Induction Potential in Mice Treated with Gemfibrozil.

Authors:  Cunzhong Shi; Luo Min; Julin Yang; Manyun Dai; Danjun Song; Huiying Hua; Gangming Xu; Frank J Gonzalez; Aiming Liu
Journal:  Basic Clin Pharmacol Toxicol       Date:  2017-05-10       Impact factor: 4.080

Review 6.  Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.

Authors:  Qinglian Zhai; Maaike van der Lee; Teun van Gelder; Jesse J Swen
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

7.  Presence or absence of microbiome modulates the response of mice organism to administered drug nabumetone.

Authors:  L Jourová; B Lišková; K Lněničková; N Zemanová; P Anzenbacher; P Hermanová; T Hudcovic; H Kozáková; E Anzenbacherová
Journal:  Physiol Res       Date:  2020-12-31       Impact factor: 1.881

Review 8.  An update on the role of intestinal cytochrome P450 enzymes in drug disposition.

Authors:  Fang Xie; Xinxin Ding; Qing-Yu Zhang
Journal:  Acta Pharm Sin B       Date:  2016-08-04       Impact factor: 11.413

9.  The Synergistic Antitumor Effect of Tanshinone IIA Plus Adriamycin on Human Hepatocellular Carcinoma Xenograft in BALB/C Nude Mice and Their Influences on Cytochrome P450 CYP3A4 In Vivo.

Authors:  Tao-Li Liu; Li-Na Zhang; Yue-Yu Gu; Mei-Gui Lin; Jun Xie; Yu-Ling Chen; Jia-Hui Liu; Xin-Lin Wu; Sui-Lin Mo
Journal:  Adv Med       Date:  2020-02-29

10.  miRNA-27b levels are associated with CYP3A activity in vitro and in vivo.

Authors:  Lena Ekström; Ilona Skilving; Marie-Louise Ovesjö; Eleni Aklillu; Hanna Nylén; Anders Rane; Ulf Diczfalusy; Linda Björkhem-Bergman
Journal:  Pharmacol Res Perspect       Date:  2015-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.